| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
CCCC
C4 Therapeutics
|
Jun 18, 2026 | BUY |
Strong Buy
+330.3% avg upside
19 analysts
|
$7.00
68.75% Upside
|
· |
|
SRRK
Scholar Rock Holding
|
Jun 18, 2026 | BUY |
Strong Buy
+20.1% avg upside
23 analysts
|
$55.00
16.28% Upside
|
· |
|
XNCR
Xencor
|
Jun 16, 2026 | BUY |
Strong Buy
+159.9% avg upside
27 analysts
|
$27.00
113.64% Upside
|
· |
|
ABVX
Abivax SA Sponsored ADR
|
Jun 16, 2026 | BUY |
Strong Buy
+20.7% avg upside
15 analysts
|
$148.00
49.25% Upside
|
+2.7% |
|
INCY
Incyte
|
Jun 15, 2026 | BUY |
Buy
+1.0% avg upside
47 analysts
|
$117.00
19.15% Upside
|
-2.9% |
|
LEGN
Legend Biotech
|
Jun 15, 2026 | BUY |
Strong Buy
+140.3% avg upside
27 analysts
|
$80.00
186.34% Upside
|
· |
|
ONC
BeOne Medicines
|
Jun 15, 2026 | BUY |
Strong Buy
+28.4% avg upside
28 analysts
|
$409.00
51.46% Upside
|
-2.1% |
|
NUVL
Nuvalent
|
Jun 09, 2026 | HOLD |
Buy
-0.3% avg upside
21 analysts
|
$124.00
0.48% Upside
|
+0.1% |
|
KURA
Kura Oncology
|
Jun 04, 2026 | BUY |
Strong Buy
+161.3% avg upside
26 analysts
|
$28.00
181.88% Upside
|
+9.1% |
|
ARVN
Arvinas Holding Company
|
Jun 03, 2026 | BUY |
Buy
+264.5% avg upside
27 analysts
|
$20.00
160.78% Upside
|
-1.6% |
|
IOVA
Iovance Biotherapeutics
|
Jun 02, 2026 | BUY |
Strong Buy
+225.8% avg upside
24 analysts
|
$11.00
181.40% Upside
|
· |
|
SMMT
Summit Therapeutics
|
Jun 02, 2026 | HOLD |
Strong Buy
+112.6% avg upside
27 analysts
|
$18.00
30.91% Upside
|
-6.7% |
|
VIR
Vir Biotechnology
|
Jun 01, 2026 | BUY |
Strong Buy
+185.4% avg upside
16 analysts
|
$30.00
227.55% Upside
|
+3.0% |
|
JAZZ
Jazz Pharmaceuticals
|
May 27, 2026 | BUY |
Strong Buy
-1.8% avg upside
35 analysts
|
$253.00
12.58% Upside
|
-2.9% |
|
RLAY
Relay Therapeutics
|
May 20, 2026 | BUY |
Strong Buy
+26.4% avg upside
19 analysts
|
$27.00
70.06% Upside
|
+21.7% |
|
MNPR
Monopar Therapeutics Inc
|
May 15, 2026 | BUY |
Strong Buy
+45.9% avg upside
18 analysts
|
$125.00
85.28% Upside
|
+0.0% |
|
TRAX
First Tracks Biotherapeutics Inc
|
May 15, 2026 | BUY |
Strong Buy
+113.2% avg upside
7 analysts
|
$40.00
129.59% Upside
|
· |
|
CRVS
Corvus Pharmaceuticals
|
May 15, 2026 | BUY |
Strong Buy
+114.5% avg upside
14 analysts
|
$28.00
135.09% Upside
|
-2.5% |
|
MGNX
MacroGenics
|
May 13, 2026 | BUY |
Buy
+326.2% avg upside
25 analysts
|
$6.00
45.24% Upside
|
+20.6% |
|
ANAB
AnaptysBio
|
May 13, 2026 | BUY |
Strong Buy
+26.1% avg upside
26 analysts
|
$75.00
30.42% Upside
|
-8.1% |
|
ORKA
Oruka Therapeutics
|
May 13, 2026 | BUY |
Strong Buy
+61.8% avg upside
16 analysts
|
$160.00
121.08% Upside
|
+12.2% |
|
TVRD
Tvardi Therapeutics
|
May 08, 2026 | SELL |
Buy
+585.4% avg upside
23 analysts
|
$3.00
13.98% Upside
|
+21.1% |
|
CLDX
Celldex
|
May 08, 2026 | BUY |
Strong Buy
+20.6% avg upside
28 analysts
|
$48.00
48.09% Upside
|
-4.7% |
|
CTMX
CytomX Therapeutics
|
May 08, 2026 | BUY |
Strong Buy
+269.6% avg upside
21 analysts
|
$16.00
442.36% Upside
|
-24.4% |
|
JANX
Janux Therapeutics Inc
|
May 08, 2026 | SELL |
Strong Buy
+217.1% avg upside
21 analysts
|
$14.00
1.63% Downside
|
+0.2% |
|
PTGX
Protagonist Therapeutics
|
May 06, 2026 | BUY |
Strong Buy
-22.1% avg upside
19 analysts
|
$119.00
5.45% Upside
|
+7.2% |
|
EXEL
Exelixis
|
May 06, 2026 | HOLD |
Strong Buy
-21.0% avg upside
33 analysts
|
$45.00
13.36% Downside
|
+9.1% |
|
SNDX
Syndax Pharmaceuticals
|
May 01, 2026 | BUY |
Strong Buy
+88.8% avg upside
27 analysts
|
$37.00
94.67% Upside
|
-0.4% |
|
KYMR
Kymera Therapeutics
|
Dec 08, 2025 | BUY |
Strong Buy
+8.9% avg upside
36 analysts
|
$119.00
31.65% Upside
|
-4.7% |
|
IVA
Inventiva
|
Apr 04, 2025 | BUY |
Strong Buy
+350.1% avg upside
16 analysts
|
$9.00
152.15% Upside
|
-55.6% |
|
BNTX
BioNTech SE
|
Mar 11, 2025 | BUY |
Strong Buy
+50.5% avg upside
26 analysts
|
$143.00
57.32% Upside
|
-7.7% |
|
GMAB
Genmab
|
Mar 04, 2025 | HOLD |
Buy
+38.3% avg upside
26 analysts
|
— | +20.8% |
|
ACRV
Acrivon Therapeutics, Inc.
|
Mar 04, 2025 | HOLD |
Strong Buy
+817.2% avg upside
13 analysts
|
— | -68.5% |
|
FHTX
Foghorn Therapeutics
|
Mar 04, 2025 | HOLD |
Strong Buy
+187.5% avg upside
17 analysts
|
— | +29.2% |
|
NRIX
Nurix Therapeutics
|
Mar 04, 2025 | HOLD |
Strong Buy
+75.6% avg upside
26 analysts
|
— | +14.0% |
|
QTTB
Q32 Bio
|
Mar 04, 2025 | HOLD |
Buy
+345.2% avg upside
24 analysts
|
— | +119.0% |
|
FATE
Fate Therapeutics
|
Mar 04, 2025 | HOLD |
Buy
+475.7% avg upside
31 analysts
|
— | +52.6% |
|
NVS
Novartis
|
Mar 04, 2025 | HOLD |
Hold
-7.5% avg upside
24 analysts
|
— | +53.7% |
|
JSPR
Jasper Therapeutics
|
Feb 27, 2025 | BUY |
Strong Buy
+6361.2% avg upside
17 analysts
|
$63.00
13807.24% Upside
|
-75.7% |
|
GB:0MGB
Genmab A/S
|
Aug 11, 2022 | HOLD |
Buy
+31.5% avg upside
22 analysts
|
$2612.00
58.98% Upside
|
· |
|
MIRM
Mirum Pharmaceuticals
|
Sep 13, 2021 | BUY |
Strong Buy
+7.0% avg upside
21 analysts
|
$37.00
65.49% Downside
|
+4.4% |
|
NTBLQ
Notable Labs
|
May 18, 2021 | BUY |
Buy
+809999900.0% avg upside
12 analysts
|
$7.00
699999899.96% Upside
|
· |
|
TRAW
Traws Pharma
|
May 18, 2021 | BUY |
Buy
+3604.6% avg upside
10 analysts
|
$60.00
6956.26% Upside
|
-93.1% |
|
DMAC
Diamedica Therapeutics
|
Mar 17, 2021 | BUY |
Strong Buy
+153.0% avg upside
12 analysts
|
$25.00
327.38% Upside
|
-74.0% |
|
TARA
Protara Therapeutics
|
Mar 11, 2021 | BUY |
Strong Buy
+1154.4% avg upside
21 analysts
|
$48.00
1106.12% Upside
|
-74.9% |
|
FR:IVA
Inventiva
|
Mar 05, 2021 | BUY |
Strong Buy
+476.8% avg upside
5 analysts
|
$25.83
745.68% Upside
|
· |
|
ALNY
Alnylam Pharma
|
Feb 22, 2021 | HOLD |
Strong Buy
+23.6% avg upside
51 analysts
|
$162.00
41.80% Downside
|
-0.9% |
|
ZYME
Zymeworks
|
Jul 14, 2020 | BUY |
Strong Buy
+40.3% avg upside
25 analysts
|
$48.00
107.40% Upside
|
+12.9% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.